scholarly journals Immunohistochemical identification of the growth factors Transforming growth factor-α, -β1, -β2 and -β3 as well as the matrixmetalloproteinase-2 in the cyclic equine endometrium

2010 ◽  
Vol 26 (2) ◽  
pp. 130-140 ◽  
Author(s):  
C Kiesow ◽  
C Ellenberger ◽  
H Sieme ◽  
H-A Schoon
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Α ◽  
Factor Α ◽  
Immunohistochemical Identification

Transforming Growth Factor α and Epidermal Growth Factor Receptor in Reactive and Malignant Mesothelial Proliferations

2004 ◽  
Vol 128 (1) ◽  
pp. 68-70
Author(s):  
Yun-Cai Cai ◽  
Victor Roggli ◽  
Eugene Mark ◽  
Philip T. Cagle ◽  
Armando E. Fraire
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Transforming Growth Factor ◽  
Malignant Tumors ◽  
Growth Factor Receptor ◽  
Transforming Growth Factor Α ◽  
Epidermal Growth ◽  
Factor Α

Abstract Background.—Growth factors such as transforming growth factor α (TGF-α) and epidermal growth factor receptor (EGFR) play an important role in cell proliferation. The immunohistochemical expression of these factors has been extensively studied in malignant tumors including mesothelioma. However, the comparative expression of these growth factors in mesothelioma and reactive mesothelial proliferations has been less well studied. Objective.—To evaluate the possible role of TGF-α and EGFR in the clinically important distinction between reactive mesothelial proliferations and malignant mesothelioma. Methods.—The expression of TGF-α and EGFR was studied in 39 cases of mesothelioma and 30 cases of reactive mesothelial proliferations by means of immunohistochemistry. Results.—Fourteen (70%) of 20 reactive mesothelial proliferations tested and 29 (76%) of 38 mesotheliomas tested expressed TGF-α. One (3%) of 30 reactive mesothelial proliferations and 17 (45%) of 39 mesotheliomas expressed EGFR. Conclusions.—These results suggest an up-regulation of EGFR in mesothelioma as compared with reactive mesothelial proliferations. This up-regulation further suggests a possible use of EGFR as an adjunct immunohistochemical test in the differential diagnosis of mesothelioma and reactive mesothelial proliferations.

scholarly journals Prospects for use of platelet-rich plasma in the treatment of rheumatoid arthritis

2021 ◽  
Vol 15 (1) ◽  
pp. 87-93
Author(s):  
S. V. Maglevaniy ◽  
E. A. Naryshkin ◽  
E. V. Chetina ◽  
M. A. Makarov
Keyword(s):  
Rheumatoid Arthritis ◽  
Growth Factors ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Platelet Rich Plasma ◽  
Local Therapy ◽  
Autologous Plasma ◽  
Transforming Growth Factor Α ◽  
Personalized Care ◽  
Factor Α

The paper reviews the data available in the literature on the mechanisms of action of platelet-rich plasma (PRP) and the experience of its use in patients with rheumatoid arthritis (RA). It defines the place of PRP in the systemic and local therapy of RA. The chemical composition of PRP and the structure of the platelet organelles included in it are described. An estimate is made for procedures to prepare platelet-rich plasma containing different concentrations of key growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor α (TGFα), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), and epidermal growth factor (EGF). The variants of PRP classifications, which take into account differences in the composition and levels of the growth factors, are considered. The experience with intra-articular injections of autologous plasma products in patients with RA and synovitis is analyzed. These findings lead to the conclusion that PRP therapy can be an effective tool to relieve inflammation and to stimulate local reparative processes in damaged joint tissues in patients with RA. Further study of the possibilities of using this method of therapy and the formation of a PRPtherapy protocol for patients with rheumatoid arthritis will provide effective personalized care to these patients.

Expression of Structural Proteins and Angiogenic Factors in Normal Arterial and Unruptured and Ruptured Aneurysm Walls

Neurosurgery ◽  
2005 ◽  
Vol 57 (5) ◽  
pp. 997-1007 ◽  
Author(s):  
Türker Kılıc ◽  
Mehran Sohrabifar ◽  
Özlem Kurtkaya ◽  
Özlem Yildirim ◽  
Ilhan Elmaci ◽  
...  
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Vessel Wall ◽  
Transforming Growth Factor ◽  
Unruptured Aneurysm ◽  
Structural Proteins ◽  
Transforming Growth Factor Α ◽  
Aneurysm Wall ◽  
Normal Vessel ◽  
Factor Α

Abstract OBJECTIVE: To identify differences in the expression of certain structural proteins and angiogenic growth factors in vessel tissues that represent different phases of the process of intracranial aneurysm formation and rupture: normal vessel wall, intact (unruptured) aneurysm wall, and ruptured vessel wall. METHODS: The novel study design involved 10 pairs of specimens (ruptured and unruptured aneurysm wall) obtained perioperatively during clipping operations in 10 patients with multiple aneurysms. All surgeries were performed within 5 days of subarachnoid hemorrhage. As controls, five circle of Willis specimens were obtained from five cadavers. Sections of each of the 25 specimens were separately immunostained for five structural proteins (collagen Types III and IV, α-smooth muscle actin, fibronectin, and laminin) and three angiogenic factors (vascular endothelial growth factor, basic fibroblast growth factor, and transforming growth factor-α). Levels of expression for each protein and factor were graded, and the average grades for each tissue group were recorded and compared. RESULTS: Among the structural proteins studied, fibronectin specifically is densely expressed in ruptured aneurysms, which is graded as 2.0. However, its expression is less prominent both in nonaneurysmal vessel wall (Grade 1.0) and unruptured aneurysm vessel wall (Grade 1.1). Contrary to fibronectin, laminin is more intensely and regularly expressed in normal vessel wall (Grade 2.7) than in ruptured (Grade 1.1) and unruptured (Grade 1.0) aneurysmal specimens. Among the angiogenic growth factors studied, transforming growth factor-α shows a peculiar grading of staining, different from the other two angiogenic factors examined, so that it is more highly expressed in normal circle of Willis specimens (Grade 2.1) than in unruptured and ruptured aneurysm walls, graded as 0.5 and 0.6, respectively. CONCLUSION: Normal vessel wall, unruptured aneurysm wall, and ruptured aneurysm wall exhibit different levels and patterns of expression for the structural proteins and regulator growth factors investigated. If one accepts the premise that immunohistochemical study has its inherent methodological problems, these results suggest that the biological mediators of aneurysm formation in a vessel wall differ from those of the biological mediators of aneurysm rupture. There was a novel finding related to fibronectin and laminin: the results indicated that a rise in the fibronectin-to-laminin ratio in an unruptured aneurysm wall may contribute to rupture. A drop in transforming growth factor-α expression in a vessel wall may also contribute to aneurysm formation.

scholarly journals Transforming growth factor-α in the mammalian brain

1989 ◽  
Vol 264 (7) ◽  
pp. 3880-3883
Author(s):  
J E Kudlow ◽  
A W Leung ◽  
M S Kobrin ◽  
A J Paterson ◽  
S L Asa
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Mammalian Brain ◽  
Transforming Growth Factor Α ◽  
Factor Α
Sign in / Sign up

Export Citation Format

Share Document